Progenics Pharmaceuticals Inc (PGNX)

6.62
0.05 0.76
NASDAQ : Health Care
Prev Close 6.57
Open 6.58
Day Low/High 6.58 / 6.62
52 Wk Low/High 3.61 / 11.15
Volume 6.54K
Avg Volume 866.40K
Exchange NASDAQ
Shares Outstanding 70.23M
Market Cap 466.30M
EPS 0.10
P/E Ratio 66.40
Div & Yield N.A. (N.A)

Latest News

Progenics Pharmaceuticals Announces The Presentation Of Data From Two Automated Bone Scan Index Studies At The 2017 ASCO Annual Meeting

Establishes Automated BSI as Prognostic Biomarker for Overall Survival

Progenics Pharmaceuticals Enters Oversold Territory (PGNX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: DMLP, GPL, HZN, LPSN Downgrades: AGLE, AKAM, ASFI, FOR, HTLD, LLY, NTZ, OSTK, PGNX, PWR, RECN, TRNC Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Relative Strength Alert For Progenics Pharmaceuticals

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Short Interest Expands By 13.2% For PGNX

The most recent short interest data has been released for the 04/13/2017 settlement date, which shows a 928,274 share increase in total short interest for Progenics Pharmaceuticals, Inc. , to 7,977,161, an increase of 13.17% since 03/31/2017.

PGNX Crosses Below Key Moving Average Level

In trading on Friday, shares of Progenics Pharmaceuticals, Inc. crossed below their 200 day moving average of $7.82, changing hands as low as $7.67 per share.

Short Interest Drops 23% For PGNX

The most recent short interest data has been released for the 03/31/2017 settlement date, which shows a 2,093,733 share decrease in total short interest for Progenics Pharmaceuticals, Inc. , to 7,048,887, a decrease of 22.90% since 03/15/2017.

What Poker Taught Me About Investing

What Poker Taught Me About Investing

I've learned that emotions have little use at a poker table; they don't in the stock market, either.

What Poker Taught Me About Investing

What Poker Taught Me About Investing

I've learned that emotions have little use at a poker table; they don't in the stock market, either.

First Week Of November 17th Options Trading For Progenics Pharmaceuticals (PGNX)

Investors in Progenics Pharmaceuticals, Inc. saw new options become available this week, for the November 17th expiration.

4 Small-Cap Biotech Stars

4 Small-Cap Biotech Stars

I'm still enthusiastic about the sector, but it is critical to also be prudent.

4 Small-Cap Biotech Stars

4 Small-Cap Biotech Stars

I'm still enthusiastic about the sector, but it is critical to also be prudent.

Biotech Premarket Movers: Progenics, Alexion, BioCryst

Biotech Premarket Movers: Progenics, Alexion, BioCryst

Progenics, Alexion and BioCryst were among the biotech stock movers in premarket trading on Thursday.

First Week of March 17th Options Trading For Progenics Pharmaceuticals (PGNX)

Investors in Progenics Pharmaceuticals, Inc. saw new options become available this week, for the March 17th expiration.

Commit To Buy Progenics Pharmaceuticals At $7, Earn 12.9% Using Options

Investors considering a purchase of Progenics Pharmaceuticals, Inc. shares, but tentative about paying the going market price of $8.79/share, might benefit from considering selling puts among the alternative strategies at their disposal.

My Top 2017 Pick: Progenics Pharmaceuticals

My Top 2017 Pick: Progenics Pharmaceuticals

This biopharma company's Relistor drug should send revenues sharply higher this year.

Top 2017 Pick: Progenics Pharmaceuticals

Top 2017 Pick: Progenics Pharmaceuticals

This biopharma company's Relistor drug should send revenues sharply higher next year.